Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
Applied Therapeutics Inc (NASDAQ: APLT) closed the day trading at $4.38 down -7.59% from the previous closing price of $4.74. In other words, the price has decreased by -$7.59 from its previous closing price. On the day, 2.89 million shares were traded. APLT stock price reached its highest trading level at $4.8887 during the session, while it also had its lowest trading level at $4.36.
Ratios:
For a better understanding of APLT, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.80 and its Current Ratio is at 0.80.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on March 26, 2024, initiated with a Outperform rating and assigned the stock a target price of $12.
On February 22, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $12.
Barclays Downgraded its Overweight to Equal Weight on January 04, 2022, whereas the target price for the stock was revised from $44 to $7.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 14 ’24 when Shendelman Shoshana sold 318,573 shares for $5.39 per share. The transaction valued at 1,717,108 led to the insider holds 3,817,814 shares of the business.
Perfetti Riccardo sold 110,804 shares of APLT for $597,234 on Mar 14 ’24. The Chief Medical Officer now owns 1,031,537 shares after completing the transaction at $5.39 per share. On Mar 14 ’24, another insider, Hansard Adam, who serves as the Chief Commercial Officer of the company, sold 48,871 shares for $5.39 each. As a result, the insider received 263,415 and left with 732,919 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, APLT now has a Market Capitalization of 463785088 and an Enterprise Value of 414663328. For the stock, the TTM Price-to-Sale (P/S) ratio is 46.94. Its current Enterprise Value per Revenue stands at 41.495 whereas that against EBITDA is -6.426.
Stock Price History:
The Beta on a monthly basis for APLT is 1.93, which has changed by 2.9818182 over the last 52 weeks, in comparison to a change of 0.2006725 over the same period for the S&P500. Over the past 52 weeks, APLT has reached a high of $9.39, while it has fallen to a 52-week low of $0.88. The 50-Day Moving Average of the stock is -21.97%, while the 200-Day Moving Average is calculated to be 43.42%.
Shares Statistics:
Over the past 3-months, APLT traded about 1.87M shares per day on average, while over the past 10 days, APLT traded about 893050 shares per day. A total of 114.24M shares are outstanding, with a floating share count of 89.01M. Insiders hold about 22.09% of the company’s shares, while institutions hold 52.03% stake in the company. Shares short for APLT as of 1711584000 were 4976918 with a Short Ratio of 2.67, compared to 1709164800 on 4330572. Therefore, it implies a Short% of Shares Outstanding of 4976918 and a Short% of Float of 5.3200003.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 3 analysts currently analyzing and rating the stock of Applied Therapeutics Inc (APLT).On average, analysts expect EPS of -$0.14 for the current quarter, with a high estimate of -$0.07 and a low estimate of -$0.18, while EPS last year was -$0.18. The consensus estimate for the next quarter is -$0.17, with high estimates of -$0.15 and low estimates of -$0.2.
Analysts are recommending an EPS of between -$0.53 and -$0.82 for the fiscal current year, implying an average EPS of -$0.72. EPS for the following year is -$0.39, with 4 analysts recommending between -$0.04 and -$0.7.
Revenue Estimates
3 analysts predict $3.33M in revenue for the current quarter. It ranges from a high estimate of $10M to a low estimate of -$-. As of the current estimate, Applied Therapeutics Inc’s year-ago sales were $10.66M, an estimated decrease of -68.80% from the year-ago figure.
A total of 3 analysts have provided revenue estimates for APLT’s current fiscal year. The highest revenue estimate was $17.2M, while the lowest revenue estimate was $1.76M, resulting in an average revenue estimate of $7.73M. In the same quarter a year ago, actual revenue was $9.99M, down -22.60% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $71.99M in the next fiscal year. The high estimate is $144.58M and the low estimate is $11.84M. The average revenue growth estimate for next year is up 831.30% from the average revenue estimate for this year.
